Compositions, kits, and methods for the diagnosis, prognosis, and monitoring of immune disorders using galectin-1

Patent metadata

Field	Value
Publication number	US-9939428-B2
Application number	US-17524908-A
Country	US
Kind code	B2
Filing date	Jul 17, 2008
Priority date	Jul 17, 2007
Publication date	Apr 10, 2018
Grant date	Apr 10, 2018

Abstract

The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in immune disorders, including Hodgkin lymphoma, anaplastic large cell lymphoma, or MLL + pre B-cell ALL. Accordingly, the invention relates to compositions, kits, and methods for diagnosing, prognosing, and monitoring immune disorders, e.g., Hodgkin lymphoma, anaplastic large cell lymphoma, or MLL + pre B-cell ALL.

First claim

What is claimed is:

1. A method of treating a subject having anaplastic large cell lymphoma that would benefit from upregulation of an immune response, the method comprising:
i) having an analysis performed to determine that the subject having anaplastic large cell lymphoma would benefit from upregulation of an immune response comprising
a) determining the level of expression of galectin-1 (Gal1) in a subject sample;
b) determining the normal level of expression of Gal1 in a control sample; and
c) comparing the level of expression of Gal1 in the subject sample to the level of expression of Gal1 in the control sample,
wherein (1) the subject sample comprises cells from anaplastic large cell lymphoma in the subject, (2) the control sample comprises cells of the same type from a control subject not having anaplastic large cell lymphoma, and (3) the level of expression of Gal1 is assessed by detecting the presence of the Gal1 protein within the cytoplasm of the cells in the samples using an antibody or antigen binding fragment thereof that specifically binds to the Gal1 protein; and

ii) administering an anti-Gal1 blocking antibody to the subject having anaplastic large cell lymphoma determined to have a significant increase in the level of expression of Gal1 in the subject sample relative to the normal level.

2. The method of claim 1 , wherein the anaplastic large cell lymphoma is ALK1 positive.

3. The method of claim 1 , wherein the anaplastic large cell lymphoma is ALK1 negative.

4. The method of claim 1 , wherein the cells are in bone marrow or a fluid selected from the group consisting of whole blood fluid, interstitial fluid, and lymph fluid.

5. The method of claim 1 , wherein the antibody is a monoclonal antibody.

6. The method of claim 1 , wherein the antibody is a polyclonal antibody.

7. The method of claim 1 , wherein the antibody is a chimeric or a humanized antibody.

8. The method of claim 1 , wherein the antibody or antigen binding fragment is a single-chain antibody.

9. The method of claim 1 , wherein the antibody or antigen binding fragment is a Fab fragment.

10. The method of claim 1 , wherein the antibody or antigen binding fragment thereof is detectably labeled.

11. The method of claim 1 , wherein the antibody or antigen binding fragment thereof specifically binds a Gal1 epitope comprising the carbohydrate binding domain.

12. The method of claim 1 , wherein the antibody or antigen binding fragment specifically binds a Gal1 epitope comprising amino acids 62-86 of human Gal1.

13. The method of claim 1 , wherein the antibody comprises an effector domain.

14. The method of claim 1 , wherein the antibody comprises an Fc domain.

15. The method of claim 1 , wherein said significant increase is an at least two-fold increase in the level of expression of Gal1 in the subject sample relative to the normal level of expression of Gal1 in the control sample.

16. The method of claim 15 , wherein said significant increase is an at least five-fold increase in the level of expression of Gal1 in the subject sample relative to the normal level of expression of Gal1 in the control sample.

Assignees

• Shipp Margaret A
• Juszczynski Przemyslaw
• Ouyang Jing
• Kutok Jeffery
• Rodig Scott
• Rabinovich Gabriel
• Dana Farber Cancer Inst Inc
• Consejo Nactional De Investigaciones Cientificias Y Tecn
• Fund Sales

Inventors

• Shipp Margaret A
• Juszczynski Przemyslaw
• Ouyang Jing
• Kutok Jeffery
• Rodig Scott
• Rabinovich Gabriel

Classifications

• G01N2800/56

  Staging of a disease; Further complications associated with the disease · CPC title

• G01N33/5052 Primary

  involving B-cells · CPC title

• A61P37/02

  Immunomodulators · CPC title

• G01N2333/4724

  Lectins · CPC title

• Y10T436/105831

  Protein or peptide standard or control [e.g., hemoglobin, etc.] · CPC title